S1S2 Spike Prote
Lab Reagents
Human IgG antibody Laboratories manufactures the s1/s2 spike prote reagents distributed by Genprice. The S1/S2 Spike Prote reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Protein. Other S1/S2 products are available in stock. Specificity: S1/S2 Category: Spike Group: Prote
Spike Trimer (S1+S2) (B.1.618 Variant), His-Tag (SARS-CoV-2) |
|||
101145 | BPS Bioscience | 100 µg | EUR 320 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.618, originally identified in India, and contains deletion 145/146YH as well as mutations E484K and D614G. The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (B.1.351 Variant), His-Tag (SARS-CoV-2) |
|||
510333-1 | BPS Bioscience | 100 µg | EUR 320 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV2 South African Variant B.1.351 and contains mutations K417N, E484K and N501Y. It also contains a C-terminal His-tag. Note that the expected MW of the S1+S2 monomer is 136kDa. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification._x000D_ |
Spike Trimer (S1+S2) (B.1.351 Variant), His-Tag (SARS-CoV-2) |
|||
510333-2 | BPS Bioscience | 1 mg | EUR 2850 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV2 South African Variant B.1.351 and contains mutations K417N, E484K and N501Y. It also contains a C-terminal His-tag. Note that the expected MW of the S1+S2 monomer is 136kDa. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification._x000D_ |
Spike Trimer (S1+S2) (B.1.1.7 Variant), His-Tag (SARS-CoV-2) |
|||
510334-1 | BPS Bioscience | 100 µg | EUR 320 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV2 United Kingdom Variant B.1.1.7. It contains mutations N501Y, A570D, D614G, P681H, T716I, S982A, D1118; deletions: 21765:6 (69-70HV), 21991:3 (44Y). This construct also contains a C-terminal His tag. Note that the expected MW of the S1+S2 monomer is 136kDa. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification. |
Spike Trimer (S1+S2) (B.1.1.7 Variant), His-Tag (SARS-CoV-2) |
|||
510334-2 | BPS Bioscience | 1 mg | EUR 2850 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV2 United Kingdom Variant B.1.1.7. It contains mutations N501Y, A570D, D614G, P681H, T716I, S982A, D1118; deletions: 21765:6 (69-70HV), 21991:3 (44Y). This construct also contains a C-terminal His tag. Note that the expected MW of the S1+S2 monomer is 136kDa. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification. |
Infectious bronchitis virus Spike glycoprotein S1 subunit (S1) |
|||
1-CSB-RP182154v | Cusabio |
|
|
Description: Recombinant Infectious bronchitis virus Spike glycoprotein S1 subunit(S1),partial expressed in E.coli |
MERS Spike S1 Recombinant protein |
|||
39-102 | ProSci | 0.1 mg | EUR 556.8 |
Description: Since April 2012, cases of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have been identified in the following countries: Saudi Arabia, Qatar, Jordan, the United Arab Emirates, Oman, Kuwait, Yemen, Lebanon, Iran, Algeria, the United Kingdom, France, Italy, Greece, Germany, the Netherlands, Austria, Tunisia, Egypt, Malaysia, Turkey and the United States of America. Coronaviruses are the cause of the common cold, SARS (severe acute respiratory syndrome) and other severe illnesses with high mortality rates, all are classified into coronavirus family. MERS-CoV is a new type of SARS found in the coronavirus family causing severe pneumonia with sudden and serious respiratory illness with high mortality rates as well. Since January 27th 2015, the WHO has reported 956 human cases, including 351 deaths. More cases of the new coronavirus strain are expected. Like in other coronaviruses, large surface spike glycoprotein is a central structural protein of this virus; it is located above the virion surface to bind and enter into the target cell. Spike protein has 2 domains- S1 and S2. The S1 domain is responsible for cellular tropism and interaction with target cell, while the S2 domain is responsible for membrane fusion. The C-terminal of S1 domain contains a receptor binding domain, and is also a potential target for vaccine development and an antigen for diagnosis. |
SARS-CoV-1 Spike Trimer (S1+S2):ACE2 Inhibitor Screening Colorimetric Assay Kit |
|||
78012 | BPS Bioscience | 96 rxns. | EUR 765 |
Description: Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a corona virus called SARS-CoV-1. It was first reported in February 2013 in Asia and the epidemic affected ~ 26 countries and resulted in more than 8000 deaths. Like SARS-CoV-2, SARS-CoV-1 Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer some protection against the viral infection. The SARS-CoV-1 Spike Trimer (S1+S2):ACE2 Inhibitor Screening Assay Kit includes the SARS-CoV-1 Spike protein in its native trimeric conformation to provide a more physiologically relevant screen for inhibitors as well as a compatible platform to investigate the specificity of SARS-CoV-2:ACE2 inhibitors._x000D_ The key to this kit is that the SARS-CoV-1 Spike Trimer (S1+S2) protein provides a more biologically relevant model than monomeric Spike RBD protein for the investigation of SARS-CoV-1/host cell interaction. Only a few simple steps on a microtiter plate are required for the assay. First, SARS-CoV-1 Spike Trimer (S1+S2) is coated on a 96-well plate. Next, Biotin-ACE2 is incubated with SARS-CoV-1 Spike Trimer (S1+S2) on the plate. Finally, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which then can be quenched and measured using a UV/Vis microplate reader. |
SARS-CoV-2 Spike Trimer (S1+S2):ACE2 Inhibitor Screening Colorimetric Assay Kit |
|||
79999 | BPS Bioscience | 96 rxns. | EUR 865 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The Spike glycoprotein is expressed on the surface of the virus as a trimer. Each Spike protein consists of two subunits, S1 and S2, and the S1 subunit has a receptor binding domain (RBD) which recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer some protection against the viral infection. The SARS-CoV-2 Spike Trimer (S1+S2) :ACE2 Inhibitor Screening Assay Kit includes the Spike protein in its native trimeric conformation to provide a more physiologically relevant screen for inhibitors of the Spike S1:ACE2 interaction._x000D_The SARS-CoV-2 Spike Trimer (S1+S2) :ACE2 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this interaction. The key to this kit is that the SARS-CoV-2 Spike Trimer (S1+S2) protein provides a more biologically relevant model than monomeric Spike RBD protein for the investigation of SARS-CoV-2/host cell interaction. Only a few simple steps on a microtiter plate are required for the assay. First, SARS-CoV-2 Spike Trimer (S1+S2) is coated on a 96-well plate. Next, Biotin-ACE2 is incubated with SARS-CoV-2 Spike Trimer (S1+S2) on the plate. Finally, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which then can be quenched and measured using a UV/Vis microplate reader. |
Spike Trimer (S1+S2) (B.1.617.1, Kappa Variant), His-Tag (SARS-CoV-2) |
|||
101144-1 | BPS Bioscience | 100 µg | EUR 320 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.617.1 also known as variant Kappa originally identified in India, and contains mutations G142D, E154K, L452R, E484Q, D614G, P681R and Q1071H. The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (B.1.617.1, Kappa Variant), His-Tag (SARS-CoV-2) |
|||
101144-2 | BPS Bioscience | 1 mg | EUR 2850 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.617.1 also known as variant Kappa originally identified in India, and contains mutations G142D, E154K, L452R, E484Q, D614G, P681R and Q1071H. The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (B.1.617.2; Delta Variant), His-Tag (SARS-CoV-2) |
|||
101147 | BPS Bioscience | 100 µg | EUR 320 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.617.2, also known as variant Delta, originally discovered in India. It contains the eight Delta variant mutations indicated below in addition to deletion 156/157. The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (XBB, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant |
|||
101660-1 | BPS Bioscience | 10 µg | EUR 230 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant XBB and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (XBB, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant |
|||
101660-2 | BPS Bioscience | 100 µg | EUR 625 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant XBB and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
Hepatitis B pre-S1+S2 Protein |
|||
abx069841-1mg | Abbexa | 1 mg | EUR 3884.4 |
SARS-CoV-2 Spike S2 Peptide |
|||
9119P | ProSci | 0.05 mg | EUR 235.5 |
Description: (IN) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike S2 Peptide |
|||
9123P | ProSci | 0.05 mg | EUR 235.5 |
Description: (CT) SARS-CoV-2 Spike peptide |